@ Hyde Park Seventh Day Adventist w/36 GBIO congs to plan how to "de-ICE Citizens Bank." We can fight back. This is one tool. #gbio #nokings

@ Hyde Park Seventh Day Adventist w/36 GBIO congs to plan how to "de-ICE Citizens Bank." We can fight back. This is one tool. #gbio #nokings

Halper Sadeh LLC Urges Shareholders to Discuss Rights Amid Potential Securities Violations Halper Sadeh LLC is encouraging shareholders of DHIL, GBIO, and CTGO to reach out to discuss potential violations of securities laws and to explore their rights.

Halper Sadeh LLC Urges Shareholders to Discuss Rights Amid Potential Securities Violations #United_States #New_York #Halper_Sadeh #DHIL #GBIO

Halper Sadeh LLC Invites Shareholders to Discuss Rights Regarding Recent Company Mergers Halper Sadeh LLC is urging shareholders of CTGO, GBIO, and CDE to contact the firm to discuss their rights related to recent company mergers. Time may be limited for action.

Halper Sadeh LLC Invites Shareholders to Discuss Rights Regarding Recent Company Mergers #USA #New_York #Halper_Sadeh_LLC #CTGO #GBIO

XOMA Royalty Enters into Agreement to Acquire Generation Bio XOMA Royalty (NASDAQ: XOMA) agreed to acquire Generation Bio (NASDAQ: GBIO) for $4.2913 per share cash plus one non-transferable contingent value right (CVR) per share. The CVR entitles holders to potential pro rata payments tied to: excess net cash over $29 million; 90%–100% of lease-savings on Generation Bio’s Cambridge office (timing-dependent); up to 90% of proceeds from Generation Bio’s Moderna license milestones and royalties; and up to 70% of proceeds from any out-license or sale of Generation Bio’s ctLNP delivery platform.The transaction will begin with a tender offer within 15 business days, requires a majority tender to close, and is expected to complete in February 2026. Roughly 15% of shares are under support agreements to tender. Advisors for the parties are disclosed.

#GBIO XOMA Royalty Enters into Agreement to Acquire Generation Bio

www.stocktitan.net/news/GBIO/xoma-royalty-e...

Generation Bio Announces Third Quarter 2025 Financial Results Generation Bio (Nasdaq: GBIO) reported third quarter 2025 results on November 5, 2025. As of September 30, 2025 the company held $89.6 million in cash, cash equivalents, and marketable securities, down from $185.2 million at December 31, 2024. R&D expenses were $21.7 million for Q3 2025 versus $15.1 million a year earlier; G&A expenses were $12.2 million versus $9.2 million a year earlier. Net loss narrowed to $5.5 million (loss per share $0.82) from $15.3 million (loss per share $2.29) in Q3 2024. In August 2025 the company paid $31.0 million to settle a lease dispute and recorded a $25.5 million gain on lease termination.

#GBIO Generation Bio Announces Third Quarter 2025 Financial Results

www.stocktitan.net/news/GBIO/generation-bio...

Trade Alerts, Monday November 3, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend according to ave directional index, Mon Nov 3rd - #XBIT #UDMY #BNGO #FSUN #GBIO #HTOO #KPET #LINC #OSUR #PNBK #RBBN #SHFS #VRE #SKLZ #PBI #OMI #MLR #KW #HNI #GBX #EIG #DFIN #CION #AHH - More: crystalequityresearch.com/trade-alerts... - #smallcap

Generation Bio Announces CEO Transition Generation Bio (Nasdaq: GBIO) announced a leadership transition effective October 31, 2025. Geoff McDonough, MD will step down as Chief Executive Officer and President and become Chair of the Board. The Board appointed Yalonda Howze, JD, currently Chief Legal Officer since April 2023, as Interim CEO and President. Jason Rhodes will step down as Board Chair and remain a director. The company described the change as a transition and expressed confidence in Howze’s interim leadership.

#GBIO Generation Bio Announces CEO Transition

www.stocktitan.net/news/GBIO/generation-bio...

Trade Alerts, Thursday October 16, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Oct 16th - #WBUY #TOYO #YDKG #UROY #SATL #OCCI #LOOP #KZR #HYPR #GBIO #FOSL #CCII #ARTV #IIIN - More: crystalequityresearch.com/trade-alerts... - #smallcap

Generation Bio Announces 1-for-10 Reverse Stock Split Generation Bio (Nasdaq: GBIO) has announced a 1-for-10 reverse stock split effective July 21, 2025, at 5:00 pm Eastern Time. The split will reduce outstanding shares from approximately 67.3 million to 6.7 million. Trading on a split-adjusted basis will begin July 22, 2025, under the same symbol "GBIO" but with a new CUSIP number (37148K 209).The reverse split, approved by stockholders on June 4, 2025, aims to increase the per-share market price to regain compliance with Nasdaq's minimum bid price requirement. The split will not affect the number of authorized shares or par value. Proportionate adjustments will be made to equity incentive plans, and stockholders will receive cash payments for any fractional shares.

#GBIO Generation Bio Announces 1-for-10 Reverse Stock Split

www.stocktitan.net/news/GBIO/generation-bio...

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results Generation Bio (GBIO) reported its Q1 2025 financial results and business updates. The company is developing first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA. The company plans to announce its lead target and portfolio strategy in mid-2025.Financial highlights include a cash position of $157.6 million as of March 31, 2025, expected to fund operations into 2H 2027. Q1 2025 results showed R&D expenses of $15.4 million (up from $14.3M in Q1 2024), G&A expenses of $8.8 million (down from $10.4M), and a net loss of $14.8 million ($0.22 per share), significantly improved from a $74.5 million loss ($1.12 per share) in Q1 2024.

#GBIO Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

www.stocktitan.net/news/GBIO/generation-bio...

Generation Bio's Breakthrough: 98% T Cell Success Powers $185M Cash Runway Through 2027 Generation Bio demonstrates 98% protein knockdown in T cell studies while maintaining $185.2M cash runway into 2027. Key pipeline decisions and IND filing scheduled for 2025-2026.

#GBIO Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/GBIO/generation-bio...

Generation Bio Pivots to Autoimmune Disease Treatment with Novel T Cell Technology Generation Bio refocuses on siRNA therapeutics for autoimmune diseases, leveraging breakthrough T cell targeting technology. First clinical trials planned for 2026.

#GBIO Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases

www.stocktitan.net/news/GBIO/generation-bio...

JUST IN: ( NASDAQ: #GBIO ) Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference

#StockMarket #News